Mirum Pharmaceuticals Presents Long-Term Data From Its LIVMARLI Studies In ALGS And PFIC Highlighted At The EASL Annual Congress, June 5-8, 2024, In Milan, Italy
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals presented long-term data from its LIVMARLI studies in Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) at the EASL Annual Congress. The data showed sustained clinical benefits and improvements in key liver markers and growth over seven years of treatment.
June 06, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals presented long-term data for LIVMARLI at the EASL Congress, showing sustained clinical benefits and improvements in liver markers and growth in patients with ALGS and PFIC.
The presentation of long-term data showing sustained clinical benefits and improvements in key liver markers and growth is likely to positively impact investor sentiment and the stock price of Mirum Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100